Insight into the current practice of ototoxicity monitoring during cisplatin therapy

The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines. Case series including retrospective medical rec...

Full description

Saved in:
Bibliographic Details
Published in:Journal of otolaryngology 2021-03, Vol.50 (1), p.19-19
Main Authors: Santucci, N M, Garber, B, Ivory, R, Kuhn, M A, Stephen, M, Aizenberg, D
Format: Article
Language:English
Subjects:
Analysis
Antimitotic agents
Antineoplastic agents
Audiogram
Audiologic
Audiology
Cancer
Cancer therapies
Chemotherapy
Cisplatin
Counseling
Drug dosages
Hair
Hearing loss
Medical centers
Medical colleges
Medical records
Medical research
Medicine, Experimental
Original
Otolaryngology
Otologic
Otology
Ototoxicity
Patients
Quality control
Quality of life
Terminology
Tinnitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines. Case series including retrospective medical records review of patients (age > 18) treated with cisplatin at University of California Davis Medical Center between January 2014 and August 2017. Patient and ototoxicity related variables were analyzed. Patients that underwent a transfer of care during treatment and with less than 3 months of follow-up were excluded. Three hundred seventy-nine patients met study criteria, of which 104 (27.4%) had a prior history of hearing loss. Prior to treatment, 196 (51.7%) patients were counseled regarding the ototoxic nature of cisplatin and 92 (24.3%) patients had a pretreatment audiogram. During treatment, 91 (24%) patients had documented otologic complaints. Only 17 patients (4.5%) patients had an audiogram ordered during their cisplatin treatment period. 130 (34.3%) patients had otologic complaints following cisplatin treatment. Audiograms were ordered for 20 (7.8%), 13 (5.1%), and 16 (6.2%) patients at 1-month, 3-month, and 6-month follow-ups, respectively. No patients in the study cohort received baseline, treatment, and post-treatment audiograms as recommended by national ototoxicity monitoring protocols. Patients with Head and Neck Cancer (HNC) represented the largest subgroup that received cisplatin (n = 122, 32.2%) and demonstrated higher rates of ototoxicity counseling (n = 103, 84.4%) and pretreatment audiograms (n = 70, 57.4%) compared to the non HNC group (n = 36, 36.2%, P 
ISSN:1916-0216
1916-0208
1916-0216
DOI:10.1186/s40463-021-00506-0